Atria Investments Inc Sells 25,588 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

Atria Investments Inc cut its holdings in shares of Phibro Animal Health Co. (NASDAQ:PAHC - Free Report) by 67.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,578 shares of the company's stock after selling 25,588 shares during the quarter. Atria Investments Inc's holdings in Phibro Animal Health were worth $283,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Sofinnova Investments Inc. acquired a new position in shares of Phibro Animal Health in the 2nd quarter valued at $3,975,000. American Century Companies Inc. boosted its stake in Phibro Animal Health by 119.6% during the second quarter. American Century Companies Inc. now owns 347,191 shares of the company's stock worth $5,822,000 after buying an additional 189,068 shares during the period. Dana Investment Advisors Inc. increased its position in shares of Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company's stock valued at $8,619,000 after acquiring an additional 75,546 shares during the last quarter. AXA S.A. purchased a new stake in shares of Phibro Animal Health in the 2nd quarter valued at approximately $906,000. Finally, Acadian Asset Management LLC raised its stake in shares of Phibro Animal Health by 6.3% in the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company's stock valued at $12,027,000 after acquiring an additional 42,299 shares during the period. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC traded down $0.02 during trading on Friday, hitting $23.74. 132,856 shares of the company were exchanged, compared to its average volume of 191,812. The company has a market cap of $961.47 million, a price-to-earnings ratio of 55.21, a PEG ratio of 0.61 and a beta of 0.51. Phibro Animal Health Co. has a 1 year low of $9.49 and a 1 year high of $25.98. The firm's fifty day moving average price is $23.16 and its 200 day moving average price is $19.99. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.34 by $0.07. The business had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. On average, sell-side analysts expect that Phibro Animal Health Co. will post 1.61 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 2.02%. The ex-dividend date of this dividend is Wednesday, November 27th. Phibro Animal Health's payout ratio is 111.63%.

Analyst Ratings Changes

Several brokerages have weighed in on PAHC. StockNews.com lowered shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Bank of America increased their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the company an "underperform" rating in a report on Friday, August 30th. JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a research note on Tuesday, September 10th. They set a "neutral" rating and a $22.00 target price for the company. Finally, Barclays increased their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an "underweight" rating in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $16.50.

Insider Buying and Selling

In related news, Director E Thomas Corcoran purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was purchased at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the acquisition, the director now owns 25,000 shares in the company, valued at approximately $500,500. This trade represents a 25.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 50.07% of the stock is currently owned by company insiders.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.